Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) stock fell -5.54% on Friday to $0.16 against a previous-day closing price of $0.17. With 7.29 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.72 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1730 whereas the lowest price it dropped to was $0.1553. The 52-week range on KPRX shows that it touched its highest point at $2.54 and its lowest point at $0.14 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.49.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KPRX was up-trending over the past week, with a rise of 6.66%, but this was down by -65.86% over a month. Three-month performance dropped to -67.47% while six-month performance fell -77.14%. The stock lost -93.19% in the past year, while it has lost -89.50% so far this year. A look at the trailing 12-month EPS for KPRX yields -1.31 with Next year EPS estimates of -0.35. For the next quarter, that number is -0.20. This implies an EPS growth rate of 19.30% for this year and 1.20% for next year.
Float and Shares Shorts:
At present, 13.06 million KPRX shares are outstanding with a float of 12.81 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.18 million, which was 1.35% higher than short shares on Jun 14, 2022. In addition to Dr. Brian M. Strem Ph.D. as the firm’s Pres, CEO, Principal Financial & Accounting Officer and Director, Dr. Eric J. Daniels M.B.A., M.D. serves as its Chief Devel. Officer.
Through their ownership of 47.78% of KPRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.20% of KPRX, in contrast to 1.53% held by mutual funds. Shares owned by individuals account for 1.09%. As the largest shareholder in KPRX with 4.18% of the stake, Geode Capital Management LLC holds 529,764 shares worth 529,764. A second-largest stockholder of KPRX, District 2 Capital LP, holds 274,040 shares, controlling over 2.16% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in KPRX, holding 93,619 shares or 0.74% stake. With a 0.99% stake in KPRX, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 125,006 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.47% of KPRX stock, is the second-largest Mutual Fund holder. It holds 59,968 shares valued at 28245.0. Vanguard Invt. Fds. ICVC – US Equ holds 0.06% of the stake in KPRX, owning 7,244 shares worth 3412.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KPRX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KPRX analysts setting a high price target of $2.50 and a low target of $1.00, the average target price over the next 12 months is $1.75. Based on these targets, KPRX could surge 1462.5% to reach the target high and rise by 525.0% to reach the target low. Reaching the average price target will result in a growth of 993.75% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. KPRX will report FY 2022 earnings on 03/08/2023. Analysts have provided yearly estimates in a range of -$0.57 being high and -$0.80 being low. For KPRX, this leads to a yearly average estimate of -$0.69. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Kiora Pharmaceuticals Inc. surprised analysts by -$0.03 when it reported -$0.26 EPS against a consensus estimate of -$0.23. The surprise factor in the prior quarter was -$0.40. Based on analyst estimates, the high estimate for the next quarter is -$0.20 and the low estimate is -$0.25. The average estimate for the next quarter is thus -$0.23.
Summary of Insider Activity:
Insiders traded KPRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has risen to 14 over the past year. The total number of shares bought during that period was 36,890 while 2,099 shares were sold.